Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADXS-504 in Biochemically Recurrent Prostate Cancer
NCT05077098Phase 1Completed
- Start
- Aug 2021
- Primary completion
- Apr 2025
- Modality
- Oncolytic Viruses, Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ADXS31-142 in prostate cancer (PCa). Primary endpoint: Incidence of adverse events at 28 days. Started Aug 2021; status: completed.
02
Drugs
ADXS31-142
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05077098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05077098.